A child enrolled in Capsida Biotherapeutics’ gene therapy trial for STXBP1 developmental and epileptic encephalopathy has died, prompting the company to pause the study while investigating the death.
The patient was the first participant in the clinical trial. Capsida said it is working to determine what happened and has notified the FDA, according to a Sept. 10 letter.
In the meantime, the clinical trial has been voluntarily paused, and the company will assess next steps for the program once more information becomes available.
STXBP1-related disorders are rare neurodevelopmental conditions associated with seizures and significant developmental delays.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.